25524results about "Respiratory disorder" patented technology

The invention relates to the field of medicinal chemistry, in particular to thiazolidinedione compounds containing quinoline structures and application of the thiazolidinedione compounds. The compound can influence the interaction between KRAS and downstream protein cRaf, namely indirectly inhibits the function of KRAS, and further inhibits the proliferation of tumor cells, and the compound and the pharmaceutical preparation thereof can be used for treating a series of diseases caused by KRAS dysfunction, mainly KRASG12D related cancers, such as KRASG12D related cancers, KRASG12D related cancers, KRASG12D related cancers, KRASG12D related cancers, KRASG12D related cancers, KRASG12D related cancers, for example, colon cancer, rectal cancer, pancreatic cancer, lung cancer, endometrial cancer, skin cancer and the like.

The invention provides application of an SRC inhibitor combined with a KRAS-G12C inhibitor to preparation of a medicine for treating KRAS-G12C mutant lung cancer and a medicine composition, and relates to the technical field of biological medicine, compared with independent use of the KRAS-G12C inhibitor, the scheme of the SRC inhibitor combined with the KRAS-G12C inhibitor can effectively inhibit proliferation and survival of KRAS-G12C mutant lung cancer cells, and the application of the SRC inhibitor combined with the KRAS-G12C inhibitor to preparation of the medicine for treating the KRAS-G12C mutant lung cancer can be used for preparing the medicine for treating the KRAS-G12C mutant lung cancer. The compound can effectively inhibit the activation of a KRAS-MARK pathway and an SRC-FAK pathway, the combination of the compound and the compound has a synergistic anti-tumor effect, and the compound and the compound can be directly combined for medication, can also be prepared into a combined preparation for treating KRAS mutant lung cancer, and have a good clinical transformation prospect.

Compositions and methods for editing deleterious mutations associated with Alpha-1 Antitrypsin Deficiency (A1AD). In particular embodiments, the invention provides methods for treating A1AD using a modified adenosine base editor with improved on-target editing and decreased off-target editing to correct mutations associated with A1AD.

To provide constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5Kb.SOLUTION: The present invention implements cellular large protein reconstitution by providing to a target cell two or more fragments of large protein fused to split inteins to promote intein-mediated trans-splicing and reconstitute the functional protein.SELECTED DRAWING: None

The technology described herein is directed to spray-dried biotherapeutic matrix compositions comprising a bacterial preparation, which is formulated for administration by inhalation. Also described herein unit dosage forms of such spray-dried biotherapeutic matrix compositions, devices comprising such pharmaceutical compositions, methods of producing such pharmaceutical compositions, and methods of treating diseases, such as bronchopulmonary diseases, among others, using such spray-dried biotherapeutic matrix compositions.

The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

To inhibit delayed dissolution of a macitentan-containing preparation after being kept under open conditions prone to humidity, and to suppress the formation of macitentan analogues.SOLUTION: According to one embodiment of the present invention, there is provided a macitentan-containing preparation comprising granules containing macitentan and an additive other than the granules, wherein the granules contain at least one kind of a disintegrant selected from the group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, carmellose, and calcium carmellose.SELECTED DRAWING: None

The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

This disclosure provides methods of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure also provides pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, and optionally comprising one or more additional CFTR-modulating agents.

To provide a compound which is a novel proline derivative, and to provide a pharmaceutical composition comprising the compound for the treatment of, for example, systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH).SOLUTION: A pharmaceutical composition comprises, as a cGAS inhibitor, a compound which is a novel proline derivative encompassed by formula (I), or a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention provides methods and means for the inhibition or neutralisation of death receptor / death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and / or the Toll-like receptor family, and / or NOD-like receptor and / or of the signalling induced via these receptors, preferably in combination with each other and / or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention discloses a nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of nano-enzymes. According to the preparation method, natural polyphenol, a cerium source and polyethylene glycol are mixed to prepare the novel polyphenol nano-enzyme, the preparation method is simple and easy to implement, the preparation cost is low, the prepared nano-enzyme has good biocompatibility, and a new way is provided for effective treatment of inflammatory diseases.

The present invention relates to the field of bioengineering, and in particular to a modified Bordetella pertussis strain, wherein the mltA gene and the pldA gene are mutated, thereby having an increased bacterial outer membrane vesicle (OMV) yield. The present invention also relates to a method for producing the modified Bordetella pertussis strain and a method for producing OMVs by the modified Bordetella pertussis strain.

The invention discloses a difluoromethoxy phenyl PDE4 inhibitor and application thereof. The compound has the effects of resisting inflammation, treating psoriasis, treating lung injury, treating chronic obstructive pulmonary disease and the like.

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFRα, PDGFRβ) kinases.

Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and / or IgE.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido [6,1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process for producing the particulate composition are also described.

Systems and methods for generating nitric oxide are disclosed. A nitric oxide (NO) generation system includes at least one pair of electrodes configured to generate a product gas containing NO from a flow of a reactant gas; and a controller configured to regulate the amount of nitric oxide in the product gas produced by the at least one pair of electrodes by utilizing duty cycle values of plasma pulses selected from a plurality of discrete duty cycles to produce a target rate of NO production based on an average of discrete production rates associated with each of the plurality of discrete duty cycles.